SCHEMBL25834169

SCHEMBL25834169

CC(C)(C)OC(=O)NCCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.54
TRPV1 Q8NER1 1/20 0.52
PLAAT3 P53816 1/20 0.50
PLAAT5 Q96KN8 1/20 0.50
PLAAT2 Q9NWW9 1/20 0.50
PLAAT4 Q9UL19 1/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
PYGL P06737 1/20 0.49
LMNA P02545 3/20 0.48
NAMPT P43490 1/20 0.48
LIPG Q9Y5X9 1/20 0.47
IDO1 P14902 2/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2B Q13224 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 2/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14830020 0.92 PYGL (0.53) TSHRCA1CA2SMN1; SMN2PYGL
SCHEMBL3114793 0.89 CA2 (0.55) CA1CA2SMN1; SMN2LMNANAMPT
SCHEMBL6677541 0.88 CA2 (0.49) TSHRTRPV1CA1CA2SMN1; SMN2
SCHEMBL17661301 0.88 CA2 (0.49) TSHRTRPV1CA1CA2SMN1; SMN2
SCHEMBL4180370 0.88 CA2 (0.49) TSHRTRPV1CA1CA2SMN1; SMN2
SCHEMBL14129641 0.85 TSHR (0.57) TSHRCA1CA2SMN1; SMN2LMNA
SCHEMBL1467824 0.84 NAMPT (0.46) TSHRCA1CA2SMN1; SMN2LMNA
SCHEMBL1817391 0.82 TSHR (0.57) TSHRTRPV1CA1CA2SMN1; SMN2
SCHEMBL25834083 0.82 KDM4E (0.63) TRPV1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL27478754 0.81 NAMPT (0.43) TSHRTRPV1CA1CA2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227451-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227451-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS MAPKAPK2, MAPK1, MAPK7 TSHR 2181/4885TRPV1 2514/4885PLAAT3 1282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.